Introduction: The objective of this study was to assess the effects of an educational program on the course of rheumatoid arthritis (RA) after 3 years.
Methods: From December 2002 to December 2003, 39 RA patients participated in a 3-day education program delivered to groups of four or five patients. Effects of the program were evaluated after 3 years in 33 patients, comparatively to baseline, based on the following variables: knowledge of RA (self-questionnaire), disease activity (DAS 28), functional impairment (health assessment questionnaire [HAQ]) and quality of life (arthritis impact measurement scale 2 [AIMS2], short-form). We also compared patient knowledge in the educational program participants and in 38 controls with RA. Direct questions were used to evaluate the program after 3 years.
Results: Patient knowledge 3 years after the education program was significantly improved compared to baseline (P<0.0001) and was significantly better than in the controls (P<0.0001). Disease activity was significantly lower in the education group after 3 years than at baseline (DAS28, 3.1 vs. 3.8, P<0.005). Neither the HAQ nor the AIMS2 scores changed significantly after 3 years compared to baseline. The replies to the direct questions indicated a very high level of overall satisfaction with the educational program.
Conclusion: An educational program tailored to patient needs can produce lasting improvements in knowledge of the disease and may help to control the activity of RA. These results warrant the development of education programs for patients with chronic inflammatory joint disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jbspin.2009.01.010 | DOI Listing |
Front Biosci (Landmark Ed)
November 2024
Department of Translational Biomedicine and Neuroscience (DiBraiN), Section of Human Anatomy and Histology, University of Bari "Aldo Moro", 70124 Bari, Italy.
Sjögren's syndrome (SS) is an autoimmune disease that can be classified as an epithelitis based on the immune-mediated attack directed specifically at epithelial cells. SS predominantly affects women, is characterized by the production of highly specific circulating autoantibodies, and the major targets are the salivary and lachrymal glands. Although a genetic predisposition has been amply demonstrated for SS, the etiology remains unclear.
View Article and Find Full Text PDFRev Bras Ortop (Sao Paulo)
November 2024
Dow Medical University of Health Sciences, Karachi, Paquistão.
Baker cyst is an abnormal enlargement of the gastrocnemius-semimembranous bursa behind the knee joint due to an exit of joint fluid. We herein report a rare case of giant Baker cyst in a rheumatic arthritic female patient. An MRI scan showed a complex, multiloculated cyst measuring 11.
View Article and Find Full Text PDFCureus
November 2024
Plastic and Reconstructive Surgery, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria (ULSSM), Lisbon, PRT.
Tuberculosis (TB) dactylitis of the hand is a rare and challenging pathology, requiring positive bacterial identification through culture or biopsy for diagnosis. Treatment is also challenging, although it typically yields an excellent response to long-term tuberculostatic therapy. We describe a case of osteoarticular tuberculous dactylitis in a 36-year-old woman with rheumatoid arthritis (RA) and a history of lymphoma.
View Article and Find Full Text PDFMed J Armed Forces India
December 2024
Professor (Pulmonary Medicine), PGIMER, Chandigarh, India.
Background: The risk factors for interstitial lung disease (ILD) in rheumatoid arthritis (RA) are inconsistent among previous studies. Furthermore, the factors associated with the emergence of the recently defined progressive fibrosing (PF) phenotype are unknown. Herein, we analyze the risk factors for ILD in RA.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!